Semaglutide and bruising at the injection site: what the evidence shows

What the trial data and prescribing information say about injection-site bruising

The STEP 1 trial (the pivotal 68-week study of semaglutide 2.4 mg that supported Wegovy's UK licence) reported injection-site reactions as one of the most common adverse events in the active treatment group. The published findings in the New England Journal of Medicine listed these reactions alongside the better-known gastrointestinal effects, confirming that bruising, itching and localised swelling were recognised as part of the medicine's established profile rather than rare surprises.

The NHS semaglutide medicine guide similarly lists injection-site bruising among the common side effects patients should be aware of, noting that it affects a meaningful proportion of users and is generally mild. Importantly, a bruise at the injection site does not mean the dose was delivered incorrectly or that the medicine has been compromised, the medicine is absorbed from the surrounding tissue regardless of a small bruise forming.

What makes semaglutide injections slightly more prone to bruising than some other subcutaneous medicines is the injection volume and the weekly frequency at a given site. Each pen delivers a fixed dose that the body absorbs over days, and the weekly interval means the same general area may be used before it has fully recovered if rotation is not practised. Evidence from post-marketing surveillance and prescribing guidance both emphasise site rotation as the single most effective preventive step. Our semaglutide overview covers the broader injection process if you want more context on how the medicine works.

The practical causes: needle angle, skin tension and thin-skinned sites

Subcutaneous injections are designed to land in the fatty tissue layer beneath the dermis, not in muscle. That tissue layer is criss-crossed with small capillaries, and a bruise forms when the needle tip or the pressure of the injection disturbs one of them. Several technique factors make this more or less likely.

Pinching the skin too hard before injecting can pull a superficial vessel into the needle's path. Conversely, injecting at a very shallow angle on a lean site (the outer thigh, for example) risks a shallower-than-intended placement that grazes more vessel-dense tissue. Speed matters too: depressing the plunger quickly can create a small pressure wave that displaces tissue. The Wegovy pen is designed to be held at 90 degrees to the skin, and following this consistently removes one of the most common variables.

People who bruise easily in general (due to age, certain medications such as anticoagulants or aspirin, or inherited variation in capillary fragility) will see more injection-site bruising than others. If you are on blood thinners or anti-platelet medicines, it is worth mentioning this to your prescriber before starting, because bruising may be more extensive and slower to clear. Our page on bruising easily on Wegovy explores that specific situation in more detail.

One thing that catches people out is the upper arm site. It is genuinely harder to inject there without assistance, and self-injecting at an inconsistent angle increases the chance of a graze. Many users who report frequent upper arm bruising find it resolves when they switch their rotation pattern to alternate between abdomen and thigh instead. For a closer look at what a bruise after a specific shot actually indicates, the page on bruising after a Wegovy shot walks through the most common scenarios.

How to reduce bruising without changing your dose or schedule

The most evidence-aligned advice comes directly from the prescribing information and the NHS: rotate injection sites every week, allow each area a minimum of a week's rest before returning to it, and follow the pen's instructions for needle-tip replacement before every injection. A blunt or damaged needle tip requires more pressure and causes more tissue disruption than a fresh one.

A few practical habits make a difference. Let the pen reach room temperature before injecting, not by warming it in your hands, but simply by taking it out of the fridge door about 20 minutes before your scheduled injection. Cold liquid entering tissue is more uncomfortable and may increase localised inflammation. Don't rub the injection site afterwards; light pressure with a clean fingertip is enough to close any micro-puncture without spreading bruising pigment through the tissue.

Ice applied for 30 seconds before the injection can constrict superficial capillaries slightly and reduce the chance of nicking one, this is a common practical tip rather than a clinical recommendation, but it does have a logical basis and causes no harm. After the injection, avoid vigorous exercise at the injection site for a couple of hours. This is not a contraindication to exercise generally; it simply lets the local tissue settle. More technique-specific guidance for people who are seeing repeated bruises in the same spot is covered on the bruise from a semaglutide shot page.

If you are considering starting Wegovy and have questions about injection technique, cost, or what the process involves, our free consultation page is the place to begin, a GPhC-registered prescriber, not an automated system, reads every submission the same day.

When a bruise needs medical attention

The vast majority of injection-site bruises are a cosmetic inconvenience and nothing more. A small discoloured patch, perhaps tender to the touch, that fades over three to seven days falls squarely within the expected range. No specific treatment is needed.

Seek medical advice if the bruise is spreading beyond the immediate injection area, is accompanied by significant warmth, is painful beyond mild tenderness, or is developing into a firm nodule (which may suggest a lipohypertrophic reaction from repeated injections at the same site). Any sign of infection (increasing redness over 24 to 48 hours, discharge, fever) warrants prompt assessment.

Separate from the injection site, if you notice bruising appearing in other places on your body without an obvious explanation while taking semaglutide, that is worth raising with your prescriber. It is not a listed side effect of the medicine itself, and another cause is more likely, but a clinician should evaluate it rather than it being attributed to Wegovy by default. You can read about the broader pattern of semaglutide and bruising easily if that applies to your situation.

Side effects including injection-site reactions can be reported to the MHRA via the Yellow Card scheme, this applies to any suspected adverse effect, however mild, and reporting helps build the post-marketing safety picture for newer medicines. Wegovy carries a Black Triangle (▼) status in the UK, meaning additional post-authorisation monitoring is in place, and Yellow Card reports contribute directly to that process. For a broader overview of how Wegovy works and what to expect during treatment, the Wegovy treatment page covers the full picture.